GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (4)
  • Natural Sciences  (4)
  • 1
    In: Annals of the New York Academy of Sciences, Wiley, Vol. 1030, No. 1 ( 2004-12), p. 555-568
    Abstract: A bstract : Artemisia has been traditionally used in Korean herbal medicine to clear damp heat and to treat uteritis and jaundice. Flavonoids isolated from Artemisia are also known to possess anti‐inflammatory activities. In this study, 5,6,3′,5′‐tetramethoxy 7,4′‐hydroxyflavone (p7F) was isolated from Artemisia absinthium . We examined in vitro and in vivo regulatory functions of p7F on the production of nitric oxide (NO), prostaglandin E 2 (PGE 2 ), and tumor necrosis factor‐α (TNF‐α) as well as the expression of inducible NO synthase (iNOS), cyclooxygenase‐2 (COX‐2), and collagen‐induced arthritis. p7F inhibited the expression or production of proinflammatory mediators such as COX‐2/PGE 2 and iNOS/NO in lipopolysaccharide (LPS)‐stimulated RAW 264.7 cells. p7F also suppressed the serum level of TNF‐α in mice treated with collagen and inhibited nuclear factor‐κB (NF‐κB) activation as well as NF‐κB promoter activity in RAW 264.7 cells stimulated with LPS. This compound directly inhibited the intracellular accumulation of reactive oxygen species in hydrogen peroxide‐stimulated RAW 264.7 cells. p7F has antioxidant activity and inhibits NF‐κB activation. Taken together, these results suggest that p7F can be clinically applied to the treatment of inflammatory diseases.
    Type of Medium: Online Resource
    ISSN: 0077-8923 , 1749-6632
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2004
    detail.hit.zdb_id: 2834079-6
    detail.hit.zdb_id: 211003-9
    detail.hit.zdb_id: 2071584-5
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Annals of the New York Academy of Sciences, Wiley, Vol. 1171, No. 1 ( 2009-08), p. 627-634
    Abstract: The aim of this study was to determine the maximum tolerated dose (MTD) and therapeutic efficacy of a newly developed CKD‐602 topoisomerase I inhibitor and cisplatin in patients with recurrent epithelial ovarian cancer. CKD‐602 (0.30 mg/m 2 daily for 5 days) and cisplatin (60 mg/m 2 on day 5) were administered to patients every 3 weeks with dose adjustment of CKD‐602 by 0.05 mg/m 2 daily until the MTD was reached. Dose‐limiting toxicity was defined as grade ≥ 3 neutropenia or thrombocytopenia for more than 4 days or accompanied by fever ≥ 38.5°C, infection, hemorrhage, or transfusion; grade ≥ 3 nonhematological toxicity except for alopecia, nausea, and vomiting. We enrolled 26 patients with recurrent epithelial ovarian cancer who had measurable disease (MD) estimated by computed tomography scan ( n = 12) and nonmeasurable disease (NMD) evaluated by serum CA‐125 levels ( n = 14). All patients received 188 cycles of CKD‐602 and cisplatin with a median number of six cycles per patient (range, 2 to 12). MTD of CKD‐602 was 0.30 mg/m 2 daily. The overall response rate was 69.2% (18/26) with 58.3% (7/12) and 78.6% (11/14) in MD and NMD, respectively. Among the responsive patients, 14 were platinum sensitive (14/18, 77.7%) and four were platinum resistant (4/8, 50.0%). The most common toxicity was grade ≥ 3 neutropenia developing in 17 patients (65.4%) and 72 cycles (38.3%). Grade 3 nausea and anorexia were the most common gastrointestinal toxicities, developing in 15 cycles (8.0%) of four patients (15.4%) and 10 cycles (5.3%) of five patients (19.3%), respectively. The median disease‐free interval was 6 months (range 0–26 months). CKD‐602 at a concentration of 0.3 mg/m 2 daily for 5 days and cisplatin at 60 mg/m 2 on day 5 every 3 weeks showed high efficacy, with acceptable toxicity, against platinum‐sensitive/resistant recurrent epithelial ovarian cancer.
    Type of Medium: Online Resource
    ISSN: 0077-8923 , 1749-6632
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 2834079-6
    detail.hit.zdb_id: 211003-9
    detail.hit.zdb_id: 2071584-5
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Wiley ; 2010
    In:  Annals of the New York Academy of Sciences Vol. 1201, No. 1 ( 2010-07), p. 65-71
    In: Annals of the New York Academy of Sciences, Wiley, Vol. 1201, No. 1 ( 2010-07), p. 65-71
    Abstract: Abstract  Diverse metabolic alterations, including mitochondrial dysfunction, have often been reported as characteristic phenotypes of senescent cells. However, the overall consequence of senescent metabolic features, how they develop, and how they are linked to other senescent phenotypes, such as enlarged cell volume, increased granularity, and oxidative stress, is not clear. We investigated the potential roles of glycogen synthase kinase 3 (GSK3), a multifunctional kinase, in the development of the metabolic phenotypes in cell senescence. The inactivation of GSK3 via phosphorylation is commonly observed in diverse cell senescences. Furthermore, subcytotoxic concentration of GSK3 inhibitor was sufficient to induce cellular senescence, accompanied by augmented anabolism, such as enhanced protein synthesis, and increased glycogenesis and lipogenesis, in addition to mitochondrial dysfunction. Anabolism was accomplished through glycogen synthase, eIF2B, and SREBP1. These metabolic features seem to contribute to an increase in cellular mass by increasing glycogen granules, protein mass, and organelles. Taken together, our results suggest that GSK3 is one of the key modulators of metabolic alteration, leading the cells to senescence.
    Type of Medium: Online Resource
    ISSN: 0077-8923 , 1749-6632
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2834079-6
    detail.hit.zdb_id: 211003-9
    detail.hit.zdb_id: 2071584-5
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Wiley ; 2005
    In:  Annals of the New York Academy of Sciences Vol. 1042, No. 1 ( 2005-05), p. 1-18
    In: Annals of the New York Academy of Sciences, Wiley, Vol. 1042, No. 1 ( 2005-05), p. 1-18
    Abstract: A bstract : Insulin resistance has been recognized as the fundamental underlying metabolic defect in the pathogenesis of metabolic syndrome, a clustering of cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, and obesity. Recent studies established that mitochondrial dysfunction is involved in insulin resistance in general and fetal origin of this state in particular. Because genes are the fundamental molecular basis of inheritance—and thus the cornerstones of evolution—a model explaining insulin resistance is based at the gene level at best. Since a certain mtDNA polymorphism, 16189T 〉 C, is associated with insulin resistance, mtDNA has to be a basic component of the gene‐based model. We developed a mitochondria‐based model that explains insulin resistance in terms of quantitative and qualitative change of the mitochondrion and its DNA. This model can accommodate several important hypotheses, such as thrifty genotype hypothesis, thrifty phenotype hypothesis, fetal insulin hypothesis, contribution of metabolic imprinting by epigenetic changes, and many other features associated with insulin resistance. We will discuss mechanisms that indicate why the perturbed initial condition of mitochondrial function should lead to the reduced insulin sensitivity.
    Type of Medium: Online Resource
    ISSN: 0077-8923 , 1749-6632
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2005
    detail.hit.zdb_id: 2834079-6
    detail.hit.zdb_id: 211003-9
    detail.hit.zdb_id: 2071584-5
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...